| Dr Frank Kolucki, MD | |
|
748 Quincy Ave, Suite 2a, Scranton, PA 18510-1739 | |
| (570) 961-0851 | |
| (570) 344-4285 |
| Full Name | Dr Frank Kolucki |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 32 Years |
| Location | 748 Quincy Ave, Scranton, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053390583 | NPI | - | NPPES |
| 001588549 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD058450L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Regional Hospital Of Scranton | Scranton, PA | Hospital |
| Wilkes-barre General Hospital | Wilkes-barre, PA | Hospital |
| Geisinger-community Medical Center | Scranton, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Scranton Quincy Clinic Company Llc | 0143487389 | 54 |
News Archive
Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."
Cell powerhouses are typically long and lean, but with brain injury such as stroke or trauma, they can quickly become bloated and dysfunctional, say scientists who documented the phenomena in real time for the first time in a living brain.
Men and women with elevated blood pressure who make healthy lifestyle changes and sustain them for up to a year and a half can substantially reduce their rates of high blood pressure and potentially decrease their heart disease risk.
The National Institutes of Health has awarded a four-year, $1.4 million grant to Cedars-Sinai's Department of Neurology to study an unexpected recent discovery: After ischemic stroke - the type caused by a clogged artery but with no bleeding into the brain - a normal protein that plays a positive role in blood clotting escapes intact arteries and damages healthy brain cells.
The Louisiana State University School of Veterinary Medicine, or LSU SVM, has received an $11 million grant to establish a Center of Biomedical Research Excellence, or COBRE.
› Verified 2 days ago
| Entity Name | Scranton Quincy Clinic Company Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508143074 PECOS PAC ID: 0143487389 Enrollment ID: O20120131000544 |
News Archive
Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."
Cell powerhouses are typically long and lean, but with brain injury such as stroke or trauma, they can quickly become bloated and dysfunctional, say scientists who documented the phenomena in real time for the first time in a living brain.
Men and women with elevated blood pressure who make healthy lifestyle changes and sustain them for up to a year and a half can substantially reduce their rates of high blood pressure and potentially decrease their heart disease risk.
The National Institutes of Health has awarded a four-year, $1.4 million grant to Cedars-Sinai's Department of Neurology to study an unexpected recent discovery: After ischemic stroke - the type caused by a clogged artery but with no bleeding into the brain - a normal protein that plays a positive role in blood clotting escapes intact arteries and damages healthy brain cells.
The Louisiana State University School of Veterinary Medicine, or LSU SVM, has received an $11 million grant to establish a Center of Biomedical Research Excellence, or COBRE.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Frank Kolucki, MD 748 Quincy Ave, Suite 2a, Scranton, PA 18510-1739 Ph: (570) 961-0851 | Dr Frank Kolucki, MD 748 Quincy Ave, Suite 2a, Scranton, PA 18510-1739 Ph: (570) 961-0851 |
News Archive
Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."
Cell powerhouses are typically long and lean, but with brain injury such as stroke or trauma, they can quickly become bloated and dysfunctional, say scientists who documented the phenomena in real time for the first time in a living brain.
Men and women with elevated blood pressure who make healthy lifestyle changes and sustain them for up to a year and a half can substantially reduce their rates of high blood pressure and potentially decrease their heart disease risk.
The National Institutes of Health has awarded a four-year, $1.4 million grant to Cedars-Sinai's Department of Neurology to study an unexpected recent discovery: After ischemic stroke - the type caused by a clogged artery but with no bleeding into the brain - a normal protein that plays a positive role in blood clotting escapes intact arteries and damages healthy brain cells.
The Louisiana State University School of Veterinary Medicine, or LSU SVM, has received an $11 million grant to establish a Center of Biomedical Research Excellence, or COBRE.
› Verified 2 days ago
Melissa Grace Marji, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 521 Mt Pleasant Dr Ste 101, Scranton, PA 18503 Phone: 570-346-7338 Fax: 570-341-3025 | |
Dr. Andrea Marissa Tomassoni, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 521 Mt Pleasant Dr, Suite 101, Scranton, PA 18503 Phone: 570-346-7338 Fax: 570-341-3025 | |
Dr. Anthony Christopher Lewis, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 531 Mt Pleasant Dr, Scranton, PA 18503 Phone: 570-342-8500 Fax: 570-558-2290 | |
Dr. Marc Howard Rabin, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 521 Mt Pleasant Dr, Suite 101, Scranton, PA 18503 Phone: 570-346-7338 Fax: 570-341-3025 | |
Brian D Wilcox, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 748 Quincy Ave, Ste 2a, Scranton, PA 18510 Phone: 570-961-0851 Fax: 570-344-4285 | |
Dr. John Drozdick, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 748 Quincy Ave, Suite 2a, Scranton, PA 18510 Phone: 570-961-0851 Fax: 570-344-4285 |